Milestones, Momentum,
& What’s Next
strategic partnerships, clinical advancements, and market milestones.
Stay informed as PanGIA Biotech advances its mission to
make early cancer detection more accessible, accurate, and globally scalable.
PanGIA Biotech Unveils AI-Driven Urine Test Data for Early Prostate Cancer Detection at ASCO 2025
PanGIA’s AI-enabled urine-based liquid biopsy will be featured in a poster session at ASCO 2025. The collaborative study highlights progress toward earlier, non-invasive detection of high-grade prostate cancer.
PanGIA Biotech Announces Upcoming ASCO 2025 Poster Presentation of Collaborative Research
PanGIA’s AI-enabled urine-based liquid biopsy will be featured in a poster session at ASCO 2025. The collaborative study highlights progress toward earlier, non-invasive detection of high-grade prostate cancer.
PanGIA Biotech Expands Leadership Team, Appoints Curtiss McNair as Vice President of Operations
PanGIA strengthens its operational leadership with the appointment of Curtiss McNair to oversee clinical lab operations, infrastructure, and systems integration as the company prepares for commercial scale.
PanGIA Biotech Announces Landmark Partnership Agreement for First Liquid Biopsy Prostate Cancer Assay in India
PanGIA’s prostate cancer assay becomes available in India through a strategic partnership with Canary Oncoceutics—marking the platform’s first international expansion and reinforcing its global potential.
PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study
PanGIA’s prostate cancer assay becomes available in India through a strategic partnership with Canary Oncoceutics—marking the platform’s first international expansion and reinforcing its global potential.